COST-EFFECTIVENESS ANALYSIS OF SAXAGLIPTIN IN THE TREATMENT OF DIABETES MELLITUS TYPE 2 IN SPAIN

被引：0
|
作者：
Ramirez de Arellano, A. [1 ]
Brosa, M. [2 ]
Franch, J. [3 ]
Mauricio, D. [4 ]
Alvarez, C. [5 ]
Sanchez-Zamorano, M. [1 ]
De Rivas, B. [5 ]
机构：
[1] Bristol Myers Squibb Iberia, Madrid, Spain
[2] Oblikue Consulting, Barcelona, Spain
[3] Red GEDAPS, Barcelona, Spain
[4] Hosp Arnau Vilanova, Lerida, Spain
[5] AstraZeneca, Madrid, Spain
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A292 / A292
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS ANALYSIS OF SAXAGLIPTIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN RUSSIA
    Arinina, E. E.
    Rashyd, M.
    VALUE IN HEALTH, 2012, 15 (04) : A172 - A172
  • [2] THE COST-EFFECTIVENESS OF SAXAGLIPTIN WHEN ADED TO METFORMIN AND SULPHONYLUREA IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN SPAIN
    Sanchez-Covisa, J.
    Franch, J.
    Mauricio, D.
    Lopez-Martinez, N.
    Chuang, L. H.
    Capel, M.
    VALUE IN HEALTH, 2014, 17 (07) : A350 - A350
  • [3] US Cost-Effectiveness of Saxagliptin in Type 2 Diabetes Mellitus
    Bergenheim, Klas
    Williams, Setareh A.
    Bergeson, Joette Gdovin
    Stern, Lee
    Sriprasert, Michelle
    AMERICAN JOURNAL OF PHARMACY BENEFITS, 2012, 4 (01) : 20 - 28
  • [4] COST-EFFECTIVENESS ANALYSIS OF DAPAGLIFLOZIN IN THE TREATMENT OF TYPE-2 DIABETES MELLITUS IN SPAIN
    Capel, M.
    Pomares, E.
    Perez-Alcantara, F.
    Simon, S.
    VALUE IN HEALTH, 2020, 23 : S508 - S508
  • [5] Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden
    Granstrom, Ola
    Bergenheim, Klas
    McEwan, Phil
    Sennfalt, Karin
    Henriksson, Martin
    PRIMARY CARE DIABETES, 2012, 6 (02) : 127 - 136
  • [6] Cost-Effectiveness of Saxagliptin in Type 2 Diabetes in the United States
    Bergenheim, Klas
    Williams, Setareh A.
    Bergeson, Joette G.
    Stern, Lee
    Sriprasert, Michelle
    DIABETES, 2011, 60 : A629 - A630
  • [7] COST-EFFECTIVENESS OF SAXAGLIPTIN COMPARED TO SITAGLIPTIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
    Hutchings, A.
    Tolley, K.
    Achana, F.
    Brereton, N. J.
    Lebmeier, M.
    Mesa, O. A.
    VALUE IN HEALTH, 2011, 14 (07) : A478 - A478
  • [8] LIRAGLUTIDE VERSUS DAPAGLIFLOZIN FOR THE TREATMENT OF PATIENTS WITH TYPE-2 DIABETES MELLITUS IN SPAIN: A COST-EFFECTIVENESS ANALYSIS
    de Arellano Serna, Ramirez A.
    Mezquita-Raya, P.
    Vega-Hernandez, G.
    Wojcik, R.
    Schlueter, M.
    VALUE IN HEALTH, 2016, 19 (07) : A674 - A674
  • [9] Screening for type 2 diabetes mellitus: A cost-effectiveness analysis
    Hoerger, TJ
    Harris, R
    Hicks, KA
    Donahue, K
    Sorensen, S
    Engelgau, M
    ANNALS OF INTERNAL MEDICINE, 2004, 140 (09) : 689 - 699
  • [10] THE COST-EFFECTIVENESS OF SAXAGLIPTIN VERSUS SULFONYLUREA (SU) IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN GERMANY
    Erhardt, W.
    Bergenheim, K.
    Townsend, R.
    Puelles, Fernandez de Troconiz J.
    McEwan, P.
    VALUE IN HEALTH, 2010, 13 (07) : A291 - A292
12345